Current and future use of hematopoietic growth factors in cancer medicine.

2.50
Hdl Handle:
http://hdl.handle.net/10541/77930
Title:
Current and future use of hematopoietic growth factors in cancer medicine.
Authors:
Mughal, Tariq I
Abstract:
Myelosuppression, in particular neutropenia and anemia are serious complications of malignancy and its treatment. Neutropenia can make patients vulnerable to potentially life-threatening infection. It often results in dose reductions and delay of planned chemotherapy, which can have a significant detrimental effect on tumour response and survival. Anemia can be associated with a range of debilitating effects, which can severely impair patients' QOL. In addition, there is some evidence recognizing anemia as a poor prognostic indicator, associated with reduced treatment efficacy. Reduction in the duration and severity of neutropenia and anemia is possible by initiation of appropriate growth factors during the first and subsequent cycles of chemotherapy. New and improved growth factor support with agents such as pegfilgrastim and darbepoetin alfa has the potential to improve the management of chemotherapy-induced neutropenia and anemia further. Thrombopoietin is currently in clinical trials to assess its potential role in the treatment of thrombocytopenia in patients with cancer.
Affiliation:
CRC Division of Medical Oncology, Christie Hospital & Institute of Cancer Research, University of Manchester School of Medicine, Manchester, UK. tmughal@freenet.co.uk
Citation:
Current and future use of hematopoietic growth factors in cancer medicine. 2004, 22 (3):121-34 Hematol Oncol
Journal:
Hematological Oncology
Issue Date:
Sep-2004
URI:
http://hdl.handle.net/10541/77930
DOI:
10.1002/hon.736
PubMed ID:
15991222
Type:
Article
Language:
en
ISSN:
0278-0232
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorMughal, Tariq I-
dc.date.accessioned2009-08-19T16:21:01Z-
dc.date.available2009-08-19T16:21:01Z-
dc.date.issued2004-09-
dc.identifier.citationCurrent and future use of hematopoietic growth factors in cancer medicine. 2004, 22 (3):121-34 Hematol Oncolen
dc.identifier.issn0278-0232-
dc.identifier.pmid15991222-
dc.identifier.doi10.1002/hon.736-
dc.identifier.urihttp://hdl.handle.net/10541/77930-
dc.description.abstractMyelosuppression, in particular neutropenia and anemia are serious complications of malignancy and its treatment. Neutropenia can make patients vulnerable to potentially life-threatening infection. It often results in dose reductions and delay of planned chemotherapy, which can have a significant detrimental effect on tumour response and survival. Anemia can be associated with a range of debilitating effects, which can severely impair patients' QOL. In addition, there is some evidence recognizing anemia as a poor prognostic indicator, associated with reduced treatment efficacy. Reduction in the duration and severity of neutropenia and anemia is possible by initiation of appropriate growth factors during the first and subsequent cycles of chemotherapy. New and improved growth factor support with agents such as pegfilgrastim and darbepoetin alfa has the potential to improve the management of chemotherapy-induced neutropenia and anemia further. Thrombopoietin is currently in clinical trials to assess its potential role in the treatment of thrombocytopenia in patients with cancer.en
dc.language.isoenen
dc.subjectAnaemiaen
dc.subjectCanceren
dc.subjectHaematopoietic Cell Growth Factors-
dc.subject.meshAnemia-
dc.subject.meshForecasting-
dc.subject.meshHematopoietic Cell Growth Factors-
dc.subject.meshHumans-
dc.subject.meshNeoplasms-
dc.subject.meshNeutropenia-
dc.titleCurrent and future use of hematopoietic growth factors in cancer medicine.en
dc.typeArticleen
dc.contributor.departmentCRC Division of Medical Oncology, Christie Hospital & Institute of Cancer Research, University of Manchester School of Medicine, Manchester, UK. tmughal@freenet.co.uken
dc.identifier.journalHematological Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.